<clinical_study>
<study_id>
<org_name>
  Amylin
</org_name>
<org_full_name>
  Amylin Pharmaceuticals
</org_full_name>
<org_study_id>
  2993-114
</org_study_id>
<nct_id>
  NCT00097500
</nct_id>
</study_id>
<brief_title>
<textblock>
  Effects of Exenatide and Insulin Glargine in Subjects with Type 2 Diabetes
</textblock>
</brief_title>
<official_title>
<textblock>
  A Phase 3, Randomized, Open Label, Comparator Controlled, Parallel Group, Multicenter Study to Compare the Effects of Exenatide and Insulin Glargine on Beta Cell Function and Cardiovascular Risk Markers in Subjects with Type 2 Diabetes Treated with Metformin who have not Achieved Target HbA1c (&lt;=7.0%)
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  Amylin Pharmaceuticals
</agency>
</lead_sponsor>
<sponsor>
<agency>
  Eli Lilly and Company
</agency>
</sponsor>
</study_sponsor>
<oversight_info>
<regulatory_authority>
  United States: Food and Drug Administration
</regulatory_authority>
</oversight_info>
<brief_summary>
<textblock>
  This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (Lantus&#174; injection) on beta-cell function in patients with type 2 diabetes mellitus using metformin.
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
</textblock>
</detailed_descr>
<status_block>
<status>
  Recruiting
</status>
<date>
  2005-03
</date>
</status_block>
<start_date>
<date>
</date>
</start_date>
<end_date>
<date>
</date>
</end_date>
<last_follow_up_date>
<date>
</date>
</last_follow_up_date>
<last_data_entry_date>
<date>
</date>
</last_data_entry_date>
<phase_block>
<phase>
  Phase 3
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Randomized
</design>
<design>
  Open Label
</design>
<design>
  Active Control
</design>
<design>
  Parallel Assignment
</design>
<design>
  Safety/Efficacy Study
</design>
<condition>
  Type 2 Diabetes Mellitus
</condition>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  exenatide
</primary_name>
</intervention>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Insulin glargine
</primary_name>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion Criteria:
    - HbA1c between 7.1% and 9.5%, inclusive.
    - Body mass index (BMI) of 25 kg/m2 to 40 kg/m2, inclusive.
    - Treated with a stable dose of metformin for at least 3 months prior to screening.  
 
  Exclusion Criteria:
    - Patients previously in a study using exenatide.
    - Treated with oral anti-diabetic medications other than metformin within 3 months of screening.
    - Treated with insulin within 3 months of screening.
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<patients>
</patients>
<expected_enrollment>
  75
</expected_enrollment>
<gender>
  Both
</gender>
<minimum_age>
  30 Years
</minimum_age>
<maximum_age>
  75 Years
</maximum_age>
</eligibility>
<location>
<facility>
<name>
  Research Site
</name>
<address>
<city>
  Helsinki
</city>
<state>
</state>
<zip>
</zip>
<country>
  Finland
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Amylin Call Center
</name>
<phone>
  919-768-9747
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Research Site
</name>
<address>
<city>
  Amsterdam
</city>
<state>
</state>
<zip>
</zip>
<country>
  Netherlands
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Amylin Call Center
</name>
<phone>
  919-768-9747
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  Research Site
</name>
<address>
<city>
  Goteborg
</city>
<state>
</state>
<zip>
</zip>
<country>
  Sweden
</country>
</address>
</facility>
<status>
  Recruiting
</status>
<contact>
<name>
  Amylin Call Center
</name>
<phone>
  919-768-9747
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<keyword>
  diabetes
</keyword>
<keyword>
  exenatide
</keyword>
<keyword>
  exendin-4
</keyword>
<keyword>
  Amylin
</keyword>
<keyword>
  Lilly
</keyword>
<initial_release_date>
</initial_release_date>
<last_release_date>
</last_release_date>
</clinical_study>
